Title: A general strategy for creating 'inactive-conformation' abl inhibitors.
Journal: Chemistry & biology 20060701
251651-26-0
26107-82-4
261952-00-5
22227-26-5
22227-25-4
16499-54-0
180465-84-3 | tert-Butyl spiro[indoline-3,4'-piperidine]-1'-carboxylate | AA0021XC | MFCD09953258
180741-44-0 | (5-Methyl-1h-pyrazol-1-yl)acetic acid | AA00227M | MFCD03419599
1810069-89-6 | 7-Methyl-1,2,3,4-tetrahydronaphthalen-1-amine hydrochloride | AA0022HS | MFCD28986162
181274-17-9 | 1H-1,2,4-Triazole-1-carboxamide, 4,5-dihydro-3-methoxy-4-methyl-5-oxo-N-[[2-(trifluoromethoxy)phenyl]sulfonyl]-, sodium salt (1:1) | AA0022PS | MFCD03792909
181772-16-7 | 3-(3,5-Bis(trifluoromethyl)phenyl)propanoic acid | AA00230P | MFCD00674033
18209-14-8 | Azirino[2',3':3,4]pyrrolo[1,2-a]indole-4,7-dione, 8-[[(aminocarbonyl)oxy]methyl]-1,1a,2,8,8a,8b-hexahydro-6,8a-dimethoxy-1,5-dimethyl-, (1aS,8S,8aR,8bS)- | AA0023A8
182362-38-5 | Hexacosanamide, N-[(1S,2R)-2-hydroxy-1-(hydroxymethyl)heptadecyl]- | AA0023NA | MFCD31563107
182808-28-2 | Ethyl 4-cyanopiperidine-1-carboxylate | AA00242A | MFCD03840836
176214-12-3 | Pyrimidine, 5-(trifluoromethyl)- | AA0024FK | MFCD11100527
1767-28-8 | 1-Pyrenol, 6-nitro- | AA0024RV | MFCD01692926